Cadrenal Therapeutics Inc (CVKD) Stock Price, Quote & News

Company Profile

Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005...

Industry: Biotechnology

Sector: Healthcare

Phone: 904 300 0701

Website: www.cadrenal.com

Address:

822 A1A North, Suite 306, Ponte Vedra, United States

MikeTechnician Jul. 9 at 6:42 PM

It's just like a wish bounce ? yes . plan.. the best you play the sparks . it's up to you bro.. The zeus loading $DBGI $VISL $CVM $CVKD No steps in signal waaa eat what you like. and die alone..

1 · Reply

MikeTechnician Jul. 9 at 4:38 PM

💊 $CVKD #NASDAQ Cadrenal Therapeutics Advances CAD-1005 Multi-Indication Strategy Biotech Research Opinion https://youtu.be/TXl0hf-BGNs?si=9DMM-Ih-NZInjXvR

0 · Reply

MikeTechnician Jul. 9 at 4:18 PM

$CVKD - Image news view AI generated

0 · Reply

MikeTechnician Jul. 9 at 3:47 PM

$CVKD Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules

0 · Reply

MikeTechnician Jul. 9 at 3:46 PM

Santa's table $CVKD - put this one on target.

0 · Reply

WallStreetSignals Jul. 9 at 1:52 PM

$CVKD #News | #CVKD #CadrenalTherapeutics raises $3 million in private placement https://www.investing.com/news/company-news/cadrenal-therapeutics-raises-3-million-in-private-placement-93CH-4769272 @followers @highlight #Thebullrunshow #Funding #Biotech #Investment #Healthcare #Startups

0 · Reply

MikeTechnician Jul. 9 at 1:29 PM

$CVKD News : Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules https://finance.yahoo.com/healthcare/articles/cadrenal-therapeutics-announces-8-8-000000641.html

0 · Reply

PaidBashar Jul. 8 at 9:52 PM

$CVKD this is one of the great biotechs of the 21st century if you ignore all the other ones

0 · Reply

topstockalerts Jul. 3 at 8:46 PM

$CVKD this one is making a pretty compelling case

0 · Reply

Orlandotrader Jul. 3 at 12:53 AM

$CVKD Let’s see what they have. July 12 Presentation.

0 · Reply

Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Jun 24, 2026, 8:00 AM EDT - 17 days ago

Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress

2026-06-18T13:07:47.000Z - 23 days ago

Cadrenal Therapeutics to file for FDA RPDD for tecarfarin in Kawasaki Disease

Jun 18, 2026, 9:00 AM EDT - 23 days ago

Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease

2026-06-15T13:15:54.000Z - 26 days ago

Cadrenal Therapeutics to initiate CAD-1005 trial

Jun 15, 2026, 8:30 AM EDT - 26 days ago

Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026

Jun 3, 2026, 9:00 AM EDT - 5 weeks ago

Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event

May 28, 2026, 9:30 AM EDT - 6 weeks ago

Cadrenal Therapeutics Transcript: Lytham Partners Spring 2026 Investor Conference

May 19, 2026, 4:30 PM EDT - 7 weeks ago

Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

May 7, 2026, 8:30 AM EDT - 2 months ago

Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA

May 7, 2026, 7:00 AM EDT - 2 months ago

Cadrenal Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 2 months ago

Cadrenal Therapeutics Earnings release: Q1 2026

May 4, 2026, 7:00 AM EDT - 2 months ago

Cadrenal Therapeutics Slides: Investor presentation

2026-04-30T13:59:21.000Z - 2 months ago

Cadrenal Therapeutics completes CAD-1005 End-of-Phase 2 meeting with FDA

Apr 30, 2026, 8:30 AM EDT - 2 months ago

Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)

HIT

Apr 21, 2026, 8:00 AM EDT - 2 months ago

Cadrenal Therapeutics Registration statement: Registration filing

2026-04-21T10:05:19.000Z - 2 months ago

Cadrenal Therapeutics files to sell 1.18M shares of common stock for holders

2026-04-07T15:40:11.000Z - 3 months ago

Cadrenal Therapeutics price target lowered to $13 from $32 at H.C. Wainwright

2026-04-01T19:36:49.000Z - 3 months ago

Cadrenal Therapeutics Inc trading halted, volatility trading pause

2026-04-01T19:35:16.000Z - 3 months ago

Cadrenal Therapeutics Inc trading resumes

Mar 31, 2026, 9:00 AM EDT - 3 months ago

Cadrenal Therapeutics Annual report: Q4 2025

Mar 31, 2026, 9:00 AM EDT - 3 months ago

Cadrenal Therapeutics Earnings release: Q4 2025

Mar 31, 2026, 8:45 AM EDT - 3 months ago

Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting

Mar 12, 2026, 3:00 PM EDT - 4 months ago

Cadrenal Therapeutics Transcript: Life Sciences Virtual Investor Forum

2026-03-12T12:21:38.000Z - 4 months ago

Cadrenal Therapeutics highlights research on 12-LOX inhibition

Mar 12, 2026, 8:00 AM EDT - 4 months ago

Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes

2026-03-02T13:37:53.000Z - 4 months ago

Cadrenal Therapeutics highlights recent 12-LOX inhibitor platform expansion

Mar 2, 2026, 8:00 AM EST - 4 months ago

Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion

2026-02-24T13:39:32.000Z - 4 months ago

Cadrenal Therapeutics announces Phase 2 results for CAD-1005

Feb 24, 2026, 8:30 AM EST - 4 months ago

Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement

Jan 15, 2026, 4:30 PM EST - 6 months ago

Cadrenal Therapeutics Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit

2026-01-12T13:35:38.000Z - 6 months ago

Cadrenal Therapeutics highlights VLX-1005 as potential therapeutic solution

Jan 12, 2026, 8:00 AM EST - 6 months ago

Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor

Dec 30, 2025, 8:00 AM EST - 6 months ago

Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System

Dec 29, 2025, 8:00 AM EST - 6 months ago

Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On

Dec 29, 2025, 7:00 AM EST - 6 months ago

Cadrenal Therapeutics Registration statement: Registration Filing

Dec 17, 2025, 9:00 AM EST - 7 months ago

Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026

Dec 12, 2025, 11:00 AM EST - 7 months ago

Cadrenal's Quiet Expansion Play Is Starting to Get Loud

Dec 12, 2025, 9:45 AM EST - 7 months ago

Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market

2025-12-11T13:25:58.000Z - 7 months ago

Cadrenal Therapeutics acquires VLX-1005 for heparin-induced thrombocytopenia

Dec 11, 2025, 8:05 AM EST - 7 months ago

Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

Dec 11, 2025, 7:00 AM EST - 7 months ago

Cadrenal Therapeutics Slides: Investor presentation

2025-12-01T14:11:18.000Z - 7 months ago

Cadrenal Therapeutics appoints Lee Golden to board of directors

PTCT

Dec 1, 2025, 9:00 AM EST - 7 months ago

Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

PTCT

Nov 19, 2025, 8:00 AM EST - 8 months ago

Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida's Executive of the Year Award

2025-11-10T14:06:44.000Z - 8 months ago

Cadrenal Therapeutics reports Q3 EPS ($1.31) vs ($2.18) last year

Nov 10, 2025, 9:00 AM EST - 8 months ago

Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 10, 2025, 9:00 AM EST - 8 months ago

Cadrenal Therapeutics Earnings release: Q3 2025

Nov 10, 2025, 9:00 AM EST - 8 months ago

Cadrenal Therapeutics Quarterly report: Q3 2025

Sep 30, 2025, 3:30 PM EDT - 10 months ago

Cadrenal Therapeutics Transcript: Lytham Partners Fall 2025 Investor Conference

Sep 29, 2025, 4:30 PM EDT - 10 months ago

Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

2025-09-15T12:15:05.000Z - 10 months ago

Cadrenal announces acquisition of assets of eXIthera Pharmaceuticals

Sep 15, 2025, 8:00 AM EDT - 10 months ago

Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera's Portfolio of Factor XIa Inhibitors

2025-08-11T12:20:21.000Z - 11 months ago

Cadrenal Therapeutics reports Q2 EPS ($1.87), consensus ($1.77)

Aug 11, 2025, 8:00 AM EDT - 11 months ago

Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 11, 2025, 7:00 AM EDT - 11 months ago

Cadrenal Therapeutics Earnings release: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 11 months ago

Cadrenal Therapeutics Quarterly report: Q2 2025

2025-08-05T10:25:11.000Z - 1 year ago

Cadrenal Therapeutics announces trial plans for tecarfarin

Aug 5, 2025, 6:00 AM EDT - 1 year ago

Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis

Jul 31, 2025, 8:00 AM EDT - 1 year ago

Cadrenal Therapeutics Proxy statement: Proxy Filing

Jul 31, 2025, 8:00 AM EDT - 1 year ago

Cadrenal Therapeutics Proxy statement: Proxy Filing

Jun 12, 2025, 8:00 AM EDT - 1 year ago

Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients

Jun 4, 2025, 8:00 AM EDT - 1 year ago

Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025

May 15, 2025, 7:30 AM EDT - 1 year ago

Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness

May 8, 2025, 4:00 PM EDT - 1 year ago

Cadrenal Therapeutics Earnings release: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Cadrenal Therapeutics Quarterly report: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update

Apr 17, 2025, 9:40 AM EDT - 1 year ago

Cadrenal Therapeutics to Present at Inaugural Centri Capital Conference at Nasdaq

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences

Mar 13, 2025, 4:05 PM EDT - 1 year ago

Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

Mar 13, 2025, 9:30 AM EDT - 1 year ago

Cadrenal Therapeutics Earnings release: Q4 2024

Mar 13, 2025, 9:30 AM EDT - 1 year ago

Cadrenal Therapeutics Annual report: Q4 2024

2025-03-04T13:21:36.000Z - 1 year ago

Cadrenal Therapeutics teams with Abbott inTECH-LVAD trial

ABT

Mar 4, 2025, 8:00 AM EST - 1 year ago

Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD

ABT

2025-02-06T14:10:14.000Z - 1 year ago

Cadrenal Therapeutics CMO Douglas Losordo departs, James Ferguson succeeds

MTNB

Feb 6, 2025, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin

Feb 5, 2025, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics to Present at BIO CEO & Investor Conference

Jan 13, 2025, 10:30 AM EST - 1 year ago

Cadrenal Therapeutics Transcript: Lytham Partners 2025 Investor Healthcare Summit

Jan 9, 2025, 8:44 AM EST - 1 year ago

Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

2024-12-31T13:10:18.000Z - 1 year ago

Cadrenal Therapeutics to initiate Phase 3 clinical trial for tecarfarin in 2025

Dec 31, 2024, 8:00 AM EST - 1 year ago

Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications

Dec 18, 2024, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings

Nov 19, 2024, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook

Nov 14, 2024, 7:00 AM EST - 1 year ago

Cadrenal Therapeutics Registration statement: Registration Filing

Nov 12, 2024, 9:00 AM EST - 1 year ago

CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS

Nov 7, 2024, 4:00 PM EST - 1 year ago

Cadrenal Therapeutics Quarterly report: Q3 2024

Nov 7, 2024, 9:00 AM EST - 1 year ago

CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE

Nov 1, 2024, 8:00 PM EDT - 1 year ago

Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds

Oct 24, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility

Oct 23, 2024, 9:00 AM EDT - 1 year ago

CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM

Oct 1, 2024, 2:00 PM EDT - 1 year ago

Cadrenal Therapeutics Transcript: Lytham Partners Fall 2024 Investor Conference

Sep 23, 2024, 4:15 PM EDT - 1 year ago

Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference

Aug 22, 2024, 9:00 AM EDT - 2 years ago

Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients

Aug 20, 2024, 3:00 PM EDT - 2 years ago

Cadrenal Therapeutics Transcript: Summer 2024 Investor Summit Virtual MicroCap Forum

Aug 20, 2024, 9:00 AM EDT - 2 years ago

Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients

Aug 20, 2024, 7:00 AM EDT - 2 years ago

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

CIA ELUT EUDA GDTC GOSS GOVX IMRN

Aug 15, 2024, 2:30 PM EDT - 2 years ago

Cadrenal Therapeutics Transcript: Sidoti Micro-Cap Virtual Conference

Aug 14, 2024, 9:00 AM EDT - 2 years ago

Cadrenal Therapeutics to Present at Upcoming Investor Conferences

MikeTechnician Jul. 9 at 6:42 PM

It's just like a wish bounce ? yes . plan.. the best you play the sparks . it's up to you bro.. The zeus loading $DBGI $VISL $CVM $CVKD No steps in signal waaa eat what you like. and die alone..

1 · Reply

MikeTechnician Jul. 9 at 4:38 PM

💊 $CVKD #NASDAQ Cadrenal Therapeutics Advances CAD-1005 Multi-Indication Strategy Biotech Research Opinion https://youtu.be/TXl0hf-BGNs?si=9DMM-Ih-NZInjXvR

0 · Reply

MikeTechnician Jul. 9 at 4:18 PM

$CVKD - Image news view AI generated

0 · Reply

MikeTechnician Jul. 9 at 3:47 PM

$CVKD Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules

0 · Reply

MikeTechnician Jul. 9 at 3:46 PM

Santa's table $CVKD - put this one on target.

0 · Reply

WallStreetSignals Jul. 9 at 1:52 PM

0 · Reply

MikeTechnician Jul. 9 at 1:29 PM

0 · Reply

PaidBashar Jul. 8 at 9:52 PM

$CVKD this is one of the great biotechs of the 21st century if you ignore all the other ones

0 · Reply

topstockalerts Jul. 3 at 8:46 PM

$CVKD this one is making a pretty compelling case

0 · Reply

Orlandotrader Jul. 3 at 12:53 AM

$CVKD Let’s see what they have. July 12 Presentation.

0 · Reply

PaidBashar Jul. 2 at 4:14 PM

$CVKD hint: the executives now have salaries for a few more years while the science goes nowhere GLTA

0 · Reply

History101 Jul. 2 at 3:46 PM

$CVKD nice pop

0 · Reply

History101 Jul. 2 at 1:22 AM

$CVKD This aged really well, share price down 60% since Dec 17

0 · Reply

History101 Jul. 2 at 1:18 AM

$CVKD June 30, 2026 direct offer, ballpark numbers: CVKD received $3MM Inv received 960k shares @ $3.12. Inv received 1,920k wrnts (2x the # shares), exerc ~ $3. OS after Dec 15, 2025 offer = 2.338MM, so shares alone (not incl wrnts) = 41% dilution. Wrnts ensure sp is capped at $3 for long time. Wrnts can be used as hedges for short positions. Sounds like an Anson deal. Dec 15, 2025 direct offer, ballpark numbers: CVKD received $1.9MM Inv received 207k shares @ $10.85 + 414k wrnts excer $10.60 Notice the nice lil pump right before the Dec 15 offer

0 · Reply

History101 Jul. 1 at 7:19 PM

$CVKD wow, management decided to actually inform investors on this dilution. The last one they did there was zero announcement, i looked all day until i was able to find an obscure article about it.

0 · Reply

MarketsParadise Jul. 1 at 5:17 PM

Small caps heating up, We are seeing some big runners lately. Take a look at ticker DRCT 💎 I believe this is the next monster runner waiting to be found: DRCT 💎 • 600K share float! • AI-powered digital advertising & marketing drive. • Extremely thin chart. • Any sustained buying pressure we look for the 5$+. $VRAX $YYGH $VMAR $CVKD .15

0 · Reply

WallStreetSignals Jul. 1 at 1:56 PM

$CVKD Latest Press Release | Cadrenal Therapeutics, Inc. (Nasdaq: #CVKD) Announces a Private Placement of Up to $8.8 Million Priced in Accordance with At-The-Market Guidelines Under Nasdaq Regulations. https://www.globenewswire.com/news-release/2026/07/01/3320268/0/en/cadrenal-therapeutics-announces-up-to-8-8-million-private-placement-priced-at-the-market-under-nasdaq-rules.html #TheBullRunShow #Investing #Biotech #NASDAQ #CVKD

0 · Reply

OpenOutcrier Jul. 1 at 12:56 PM

$CVKD (-8.1% pre) Cadrenal Therapeutics launches up to $8.8M private placement https://ooc.bz/l/106649

0 · Reply

RotterdamTrade Jul. 1 at 9:57 AM

$CVKD 3.15 for the shares ? Nice took some because fear of dillution is now gone.

0 · Reply

focafoca99 Jul. 1 at 4:31 AM

$CVKD initiated a private placement priced at-market under Nasdaq rules, targeting up to $8.8 million to extend cash runway into 2027.

0 · Reply

STACKD0E Jul. 1 at 2:14 AM

$JEM $CVKD $BTOG ✨️

0 · Reply

VAULTF600 Jun. 25 at 7:54 PM

$CVKD can it really sink further?

2 · Reply

Market Cap	8.63M
Revenue (ttm)	0.00
Net Income (ttm)	-13.24M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	40,800
Avg Vol	77,706
Day's Range	N/A - N/A
Shares Out	2.87M
Stochastic %K	0%
Beta	1.73
Analysts	Strong Sell
Price Target	$27.67